Skip to main content
SpringerLink
Log in
Book cover

NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders: from Genes to Therapeutics pp 223–244Cite as

NPY and chronic neurodegenerative disease

  • Chapter

  • 439 Accesses

Part of the book series: Experientia Supplementum ((EXS,volume 95))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chronwall B, Zukowska Z (2004) Neuropeptide Y, ubiquitous and elusive. Peptides 25: 359–363

    Article  CAS  PubMed  Google Scholar 

  2. Conlon J (2002) The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 23: 269–278

    PubMed  Google Scholar 

  3. Baraban S, Tallent M (2004) Interneuron Diversity series — Interneuronal neuropeptides-endogenous regulators of neuronal excitability. Trends Neurosci 27: 136–142

    Article  Google Scholar 

  4. Delafuente M, Bernaezi I, Del Rio M, Hernanz A (1993) Stimulation of murine peritoneal macrophage functions by neuropeptide Y and peptide YY. Involvement of protein kinase C. Immunology 80: 259–265

    CAS  Google Scholar 

  5. Dimitrijevic M, Stanojevic S, Vujic V, Beck-Sickinger A, von Hörsten S (2005) Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors. Regul Pept 124: 163–172

    Article  CAS  PubMed  Google Scholar 

  6. Herzog H (2003) Neuropeptide Y and energy homeostasis: Insights from Y receptor knockout models. Eur J Pharmacol 480: 21–29

    Article  CAS  PubMed  Google Scholar 

  7. Kaga T, Fujimiya M, Inui A (2001) Emerging functions of neuropeptide Y Y(2) receptors in the brain. Peptides 22: 501–506

    Article  CAS  PubMed  Google Scholar 

  8. Thorsell A, Michaelkiewicz M, Dumont Y, Quirion R, Carerlotto L, Rimondini R, Mathe A, Heilig M (2000) Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci 97: 12852–12857

    Article  CAS  PubMed  Google Scholar 

  9. Zukowska Z, Wahlestedt C (2005) Origin and actions of neuropeptide Y in the cardiovascular system. In: W Colmers and C Wahlestedt, (eds): The biology of Neuropeptide Y and related peptides. Humana press, Totowa, NJ, 315–387

    Google Scholar 

  10. Adrian T, Allen J, Bloom S, Ghatei M, Rossor M, Roberts G, Crow T, Tatemoto K, Polak J (1983) Neuropeptide Y distribution in human brain. Nature 306: 584–586

    Article  CAS  PubMed  Google Scholar 

  11. Beal MF, Mazurek M, McKee M (1987) The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer’s disease striatum. Neurosci Lett 79: 201–206

    Article  CAS  PubMed  Google Scholar 

  12. Busch Sorensen M, Sheikh S, O Hare M, Tortora O, Schwartz T, Gammeltoft S (1989) Regional distribution of neuropeptide Y and its receptor in the porcine central nervous system. J Neurochem 52: 1545–1552

    CAS  PubMed  Google Scholar 

  13. Dawbarn D, Rossor M, Mountjoy C, Roth M, Emson P (1986) Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. Neurosci Lett 70: 154–159

    Article  CAS  PubMed  Google Scholar 

  14. Kohler C, Eriksson L, Davies S, Chan-Palay V (1986) Neuropeptide Y innervation of the hippocampal region in the rat and monkey brain. J Comp Neurol 244: 384–400

    CAS  PubMed  Google Scholar 

  15. Wu Y, Zhang D, Lou D, Fan Y, Aronow B, Xu M, Zhang J (2004) C-fos regulates neuropeptide Y expression in mouse dentate gyrus. Neurosci Lett 363: 6–10

    Article  CAS  PubMed  Google Scholar 

  16. Braak H, Braak E, Yilmazer D, De Vos R, Jansen E, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103: 455–490

    Article  CAS  PubMed  Google Scholar 

  17. Rossler M, Zarski R, Bohl J, Ohm T (2002) Stage-dependent and sector specific neuronal loss in hippocampus during Alzheimer’s disease. Acta Neuropathol 103: 363–369

    PubMed  Google Scholar 

  18. Panegyres P (2004) The contribution of the study of neurodegenerative disorders to the understanding of human memory. Q J Med 97: 555–567

    CAS  Google Scholar 

  19. Cadiacio C, Milner T, Gallagher M, Pierce J (2003) Hilar neuropeptide Y interneuron loss in the aged rat hippocampal formation. Exp Neurol 183: 147–158

    Article  CAS  PubMed  Google Scholar 

  20. Deller T, Leranth C (1990) Synaptic connections of neuropeptide Y (NPY) immunoreactive neurons in the hilar area of the rat hippocampus. J Comp Neurol 300: 433–447

    Article  CAS  PubMed  Google Scholar 

  21. Diez M, Koistinaho J, Kahn K, Games D, Hokfelt T (2000) Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F-beta amyloid precursor protein-initial observations. Neurosci 100: 259–286

    Article  CAS  Google Scholar 

  22. Gustafson E, Smith K, Durkin M, Walker M, Gerald C, Weinshank R, Branchek T (1997) Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res Mol Brain Res 46: 223–235

    CAS  PubMed  Google Scholar 

  23. Redrobe J, Dumont Y, St-Pierre J, Quirion R (1999) Multiple receptors for neuropeptide Y in the hippocampus: Putative roles in seizures and cognition. Brain Res 848: 153–166

    Article  CAS  PubMed  Google Scholar 

  24. Terenghi G, Polak Q, Hamid E, O Brian P, Denny S, Legon J, Dixon C, Minth S, Palay G, Yasargil G (1987) Localization of neuropeptide Y mRNA in neurons of human cerebral cortex by means of in situ hybridization with a complementary RNA probe. Proc Natl Acad Sci 84: 7315–7318

    CAS  PubMed  Google Scholar 

  25. Aoki C, Pickel V (1989) Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons. J Neurosci 9: 4333–4354

    CAS  PubMed  Google Scholar 

  26. Kerkerian L, Salin P, Nieoullon A (1990) Cortical Regulation of Striatal Neuropeptide Y (NPY)-Containing Neurons in the Rat. Eur J Neurosci 2: 181–189

    PubMed  Google Scholar 

  27. Kohler C, Schultzberg M, Radesater A (1987) Distribution of neuropeptide Y receptors in the rat hippocampal region. Neurosci Lett 75: 141–146

    Article  CAS  PubMed  Google Scholar 

  28. Parent A, Cote P, Lavoie B (1995) Chemical anatomy of primate basal ganglia. Prog Neurobiol 46: 131–197

    Article  CAS  PubMed  Google Scholar 

  29. Pickel V, Chan J, Veznedaroglu E, Miltner T (1995) Neuropeptide Y and dynorphin-immunoreactive large dense-core vesicles are strategically localized for presynaptic modulation in the hippocampal formation and substantia nigra. Synapse 19: 160–169

    Article  CAS  PubMed  Google Scholar 

  30. Aoki C, Pickel V (1990) Neuropeptide Y in cortex and striatum. Ultrastructural distribution and coexistence with classical neurotransmitters and neuropeptides. Ann N Y Acad Sci 611: 186–205

    CAS  PubMed  Google Scholar 

  31. Chan-Palay V, Lang W, Haessler U, Kohler C, Yasargil G (1986) Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer’s type dementia. J Comp Neurol 248: 376–394

    CAS  PubMed  Google Scholar 

  32. Nag S, Yee B, Tang F (1999) Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1–40). Brain Res Bull 50: 251–262

    Article  CAS  PubMed  Google Scholar 

  33. Baraban S, Hollopeter G, Erickson J, Schwartzkroin P, Palmiter R (1997) Knockout mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 17: 8927–8936

    CAS  PubMed  Google Scholar 

  34. Kishi T, Aschkenasi C, Choi B, Lopez M, Lee C, Liu H, Hollenberg, Friedman J, Elmquist J (2005) Neuropeptide Y Y1 receptor mRNA in rodent brain: Distribution and colocalization with melanocortin-4 receptor. J Comp Neurol 482: 217–243

    Article  CAS  PubMed  Google Scholar 

  35. Wolak M, Dejoseph M, Cator A, Mokash A, Brownfield M, Urban J (2003) Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 464: 285–311

    Article  CAS  PubMed  Google Scholar 

  36. Vezzani A, Sperk G, Colmers W (1999) Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 22: 25–30

    Article  CAS  PubMed  Google Scholar 

  37. Colmers W, Lukowiak K, Pittman Q (1988) Neuropeptide Y action in the rat hippocampal slice: Site and mechanism of presynaptic inhibition. J Neurosci 8: 3827

    CAS  PubMed  Google Scholar 

  38. Qian J, Colmers W, Saggau P (1997) Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+J Neurosci 17: 8169–8177

    CAS  PubMed  Google Scholar 

  39. Silva A, Carvalho A, Cavalho C, Malva J (2001) Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J Neurochem 79: 286–296

    Article  CAS  PubMed  Google Scholar 

  40. Smialowska M, Wieronska J, Szewczyk B (2003) Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Polish J Pharmacol 55: 979–986

    CAS  Google Scholar 

  41. Flood J, Baker M, Hernandez E, Morley J (1989) Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res 503: 73–82

    Article  CAS  PubMed  Google Scholar 

  42. Flood J, Fernandez E, Morley J (1987) Modulation of memory processing by neuropeptide Y. Brain Res 421: 280–290

    Article  CAS  PubMed  Google Scholar 

  43. Thompson K, Orfila J, Achanta P, Martinez J (2003) Gene expression associated with in vivo induction of early phase-long-term potentiation (LTP) in the hippocampal mossy fiber-Cornus Ammonis (CA)3 pathway. Cell Mol Biol (Noisy-le-grand) 49: 1281–1287

    CAS  Google Scholar 

  44. Dere E, Silva M, Huston J (2004) Higher order memories for objects encountered in different spatio-temporal contexts in mice: Evidence for episodic memory. Rev Neurosci 15: 240

    Google Scholar 

  45. Redrobe J, Dumont Y, Herzog H, Quirion R (2004) Characterization of neuropeptide Y, Y2 receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci 22: 159–166

    CAS  PubMed  Google Scholar 

  46. Gold PE (2003) Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80: 194–210

    CAS  PubMed  Google Scholar 

  47. Isacson O, Seo H, Lin L, Albeck D, Granholm A (2002) Alzheimer’s disease and Down’s syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 25: 79–84

    Article  CAS  PubMed  Google Scholar 

  48. Mufson E, Ginsberg S, Ikonomovic M, Dekosky S (2003) Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26: 233–242

    Article  CAS  PubMed  Google Scholar 

  49. Nag S, Tang F (1998) Cholinergic lesions of the rat brain by ibotenic acid and 192 IgG-saporin: effects on somatostatin, substance P and neuropeptide Y levels in the cerebral cortex and the hippocampus. Neurosci Lett 252: 83–86

    Article  CAS  PubMed  Google Scholar 

  50. D’Hooge R, De Deyn P (2001) Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 60

    Google Scholar 

  51. Shukitt Hale B, McEwen J, Szprengiel A, Joseph J (2004) Effect of age on the radial arm water maze-A test of spatial and learning memory. Neurobiol Aging 25: 223–229

    PubMed  Google Scholar 

  52. Carvajal C, Vercauteren F, Dumont Y, Michalkiewicz M, Quirion R (2004) Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non spatial learning. Behav Brain Res 153: 471–480

    Article  CAS  PubMed  Google Scholar 

  53. Selkoe D, Schenk D (2003) Alzheimer’s disease: Molecular understanding predicts amyloid based therapeutics. Annu Rev Pharmacol Toxicol 43: 545–584

    Article  CAS  PubMed  Google Scholar 

  54. Buckner R (2004) Memory and executive function in aging and AD: Multiple factors that cause decline and reserve factors that compensate. Neuron 44: 195–208

    Article  CAS  PubMed  Google Scholar 

  55. Iqbal K, Adel A, Chen SEA (2005) Tau pathology in Alzheimer’s disease and other tauopathies. Biochim Biophys Acta 1739: 198–210

    CAS  PubMed  Google Scholar 

  56. Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G (1992) Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson’s disease, multiple system atrophy and dementia of the Alzheimer type. J Neural Transm 4: 191–205

    CAS  Google Scholar 

  57. Minthon L, Edvinsson L, Ekman R, Gustafson L (1990) Neuropeptide levels in Alzheimer’s disease and dementia with frontotemporal degeneration. J Neural Transm 30: 57–67

    CAS  Google Scholar 

  58. Atack J, Beal M, May C, Kaye J, Mazurek M, Kaya A, Rapaport S (1988) Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and dementia of the Alzheimer type with and without extrapyramidal signs. Arch Neurol 45: 269–274

    CAS  PubMed  Google Scholar 

  59. Edvinsson L, Minthons L, Ekman R, Gustafson L (1993) Neuropeptides in cerebrospinal fluid of patients with Alzheimer’s disease and dementia with frontoteomporal lobe degeneration. Dementia 4: 167–171

    CAS  PubMed  Google Scholar 

  60. Heilig M, Sjogren M, Blennow K, Ekmann R, Wallin A (1995) Cerebrospinal fluid neuropeptides in Alzheimer’s disease and vascular dementia. Biol Psychiatry 38: 210–216

    Article  CAS  PubMed  Google Scholar 

  61. Nilsson C, Brinkmalm A, Minthon L, Blennow K, Ekman R (2001) Processing of neuropeptide Y, galanin and somatostatin in the cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal deentia. Peptides 22: 2105–2112

    Article  CAS  PubMed  Google Scholar 

  62. Chan-Palay V (1987) Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: Co-existence with neuropeptide Y neurons and effects in Alzheimer-type dementia. J Comp Neurol 260: 201–223

    Article  CAS  PubMed  Google Scholar 

  63. Kowall N, Beal M (1988) Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer’s disease. Ann Neurol 23: 105–114

    Article  CAS  PubMed  Google Scholar 

  64. Gabriel S, Bierer L, Harotunian V, Purohit D, Perl D, Davis K (1993) Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer’s disease cerebral cortex. Neurosci Lett 155: 116–120

    Article  CAS  PubMed  Google Scholar 

  65. Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold K, Hokfelt T (2003) Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis 14: 579–594

    Article  CAS  PubMed  Google Scholar 

  66. Games D, Adams D, Alessandrini R, Barnour R, Berthelette P, Blackwell C, Carr T, Clemes J, Donaldson T, Gillespie F et al. (1995) Alzheimer’s type neuropathology in transgenic mice over expressing V717F B amyloid precursor protein. Nature 373: 523–527

    Article  CAS  PubMed  Google Scholar 

  67. Sturchler Pierrrat C, Abramowski D, Duke M, Wiederhold K, Mistl C et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease like pathology. Proc Nat Acad Sci 94: 13287–13292

    Google Scholar 

  68. Irizarry M, McNamara M, Fedorchak K, Hsiao K, Hyman B (1997) APPsw transgenic mice develop age related A beta deposits and neuropil abnormalities but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965–997

    CAS  PubMed  Google Scholar 

  69. Schwaab C, Hosokawa M, McGeer P (2004) Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188: 52–64

    Google Scholar 

  70. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Ab elevation and amyloid plaques in transgenic mice. Science 274: 99–102

    Article  CAS  PubMed  Google Scholar 

  71. Sasaki A, Shoji M, Harigaya Y, Kawarabayashi T et al. (2002) Amyloid core plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia and the lack of paired helical filament typed, dystrophic neurites. Virchows Arch 441: 358–367

    CAS  PubMed  Google Scholar 

  72. Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M (2001) Abeta amyloidosis induces the initial stage of tau accumulation in APPsw mice. Neurosci Lett 299: 169–172

    Article  CAS  PubMed  Google Scholar 

  73. Oddo S, Billings L, Kesslak P, Cribbs D, Leferla F (2004) Abeta immunotherapy leads to clearance of early but not late hyperphorphorylated tau aggregates via the proteosome. Neuron 43: 321–332

    Article  CAS  PubMed  Google Scholar 

  74. Oddo S, Caccamo A, Kitazawa M, Tseng B, Leferla F (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24: 1063–1070

    Article  CAS  PubMed  Google Scholar 

  75. Kawaguchi Y, WILSON C, Augood S, Emson P (1995) Striatal interneurones: Chemical, physiological and morphological characterization. Trends Neurosci 18: 527–535

    Article  CAS  PubMed  Google Scholar 

  76. Kowall N, Ferrante R, Beal M, Richardson E, Sofroniew M, Cuello A, Martin J (1987) Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. Neurosci 20: 817–828

    Article  CAS  Google Scholar 

  77. Cannizzaro C, Tel B, Rose S, Eng B, Jenner P (2003) Increased neuropeptide Y mRNA expression in striatum in Parkinson’s disease. Mol Brain Res 110: 169–176

    Article  CAS  PubMed  Google Scholar 

  78. Vuillet J, Kerkerian L, Kachidian P, Bosler O, Nieoullon A (1989) Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferent fibers and neuropeptide Y-containing neurons in the rat striatum. Neurosci Lett 100: 99–104

    Article  CAS  PubMed  Google Scholar 

  79. Vuillet J, Kerkerian L, Salin P, Nieoullon A (1989) Ultrastructural features of NPY-containing neurons in the rat striatum. Brain Res 477: 241–251

    Article  CAS  PubMed  Google Scholar 

  80. Figueredo Cardenas G, Chen Q, Reiner A (1997) Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146: 444–457

    CAS  PubMed  Google Scholar 

  81. Unger J, Lange W (1992) NADPH-diaphorase-positive cell populations in the human amygdale and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer’s disease. Acta Neuropathol (Berl) 83: 636–646

    Article  CAS  PubMed  Google Scholar 

  82. Unger J, SCHMIDT Y (1994) Neuropeptide Y and somatostatin in the neocortex of young and aging rats: Response to nuclear basalis lesions. J Chem Neuroanat 7: 25–34

    Article  CAS  PubMed  Google Scholar 

  83. Wink DA, Feelisch M, Vodovotz Y, Fukuto J, Grisham MB (1999) The Chemical Biology of Nitric Oxide. In: DL Gilbert and CA Colton (eds): Reactive Oxygen Species in Biological Systems: An Interdisciplinary Approach. Kluwer Academic, New York, 245–291

    Google Scholar 

  84. Adewale A, Macarthur H, Westfall T (2005) Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Reg Peptides 129: 73–78

    Article  CAS  Google Scholar 

  85. Iwakiri M, Mizukami K, Ikonomovic M, Ishikawa M, Hidaka S, Abrahamsco E, Dekosky S, Asada T (2005) Changes in hippocampal GABABR1 subunit expression in Alzheimer’s patients: association with Braak staging. Acta Neuropathol 109: 467–474

    Article  CAS  PubMed  Google Scholar 

  86. Obuchowicz E, Antikiewicz-Michaluk L, Romanska I, Herman Z (2003) Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTPtreated mice. J Neural Transm 110: 1375–1391

    Article  CAS  PubMed  Google Scholar 

  87. Kerkerian L, Salin P, Nieoullon A (1988) Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience 26: 809–817

    Article  CAS  PubMed  Google Scholar 

  88. McCullough L, Westfall T (1995) Neuropeptide Y inhibits depolarization stimulated catecholamine synthesis in rat pheochromocytoma. Eur J Pharmacol 287: 271–277

    Article  CAS  PubMed  Google Scholar 

  89. Tsuda K, Tsuda S, Nisho I, Goldstein M, Masuyama Y (1997) Modulation of 3H-dopamine release by neuropeptide Y in rat striatal slices. Eur J Pharmacol 321: 5–11

    Article  CAS  PubMed  Google Scholar 

  90. Feigin A, Zgaljardic D (2002) Recent advances in Huntington’s disease: Implication for experimental therapeutics. Curr Opin Neurol 15: 483–489

    Article  PubMed  Google Scholar 

  91. Li H, Li S, Yu Z, Shelbourne P, Li X (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington’s disease mice. J Neurosci 21: 8473–8481

    CAS  PubMed  Google Scholar 

  92. Sieradzan K, Mann D (2001) The selective vulnerability of nerve cells in Huntington’s disease. Neuropath Appl Neurobiol 27: 1–21

    CAS  Google Scholar 

  93. Beal F, Brouillet E, Jenkins B, Ferrante R, Kowall N, Miller J, Storey E, Srivastava R, Rosen B, Hyman B (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181–4192

    CAS  PubMed  Google Scholar 

  94. Figueredo Cardenas G, Harris C, Anderson K, Reiner A (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic cid mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 149: 356–372

    CAS  PubMed  Google Scholar 

  95. Beal F, Mazurek M, Ellison D, Swartz K, McGarvey U, Bird E, Martin J (1988) Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington’s disease. Ann Neurol 23: 562–569

    Article  CAS  PubMed  Google Scholar 

  96. Mazurek M, Garside S, Beal M (1997) Cortical peptide changes in Huntington’s disease may be independent of striatal degeneration. Ann Neurol 41: 540–547

    Article  CAS  PubMed  Google Scholar 

  97. Luthi Carter R, Strand A, Peters N et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Human Mol Genet 9: 1259–1271

    CAS  Google Scholar 

  98. Figueredo Cardenas G, Anderson K, Chen Q, Veenman C, Reiner A (1994) Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 129: 37–56

    CAS  PubMed  Google Scholar 

  99. Kumar U (2004) Characterization of striatal cultures with the effect of QUIN and NMDA. Neurosci Res 49: 29–38

    Article  CAS  PubMed  Google Scholar 

  100. Corti O, Hampe C, Darios F, Ibanez P, Ruberg M, Brice A (2005) Parkinson’s disease: from causes to mechanisms. C R Biol 328: 131–142

    CAS  PubMed  Google Scholar 

  101. Eriksen J, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62: 353–357

    Article  PubMed  Google Scholar 

  102. Cookson M (2005) The biochemistry of Parkinson’s disease. Annu Rev Biochem 74: 29–52

    Article  CAS  PubMed  Google Scholar 

  103. Allen J, Cross A, Crow T, Javoy-Agid F, Agid Y, Bloom S (1985) Dissociation of neuropeptide Y and somatostatin in Parkinson’s disease. Brain Res 337: 197–200

    Article  CAS  PubMed  Google Scholar 

  104. Abrous D, Lemoal M, Herman J (1994) The increase in striatal neuropeptide Y immunoreactivity induced by neonatal dopamine-depleting lesions in rats is reversed by intrastriatal dopaminerich transplants. Brain Res 656: 169–173

    Article  CAS  PubMed  Google Scholar 

  105. Gabriel S, Davidson M, Haroutunian V, Powchik P, Bierer L, Purohit D, Perl D, Davis K (1996) Neuropeptide deficits in schizophrenia versus Alzheimer’s disease cerebral cortex. Biol Psych 39: 82–91

    CAS  Google Scholar 

  106. Gaspar P, Duyckaerts C, Febvret A, Benoit R, Beck B, Berger B (1989) Subpopulations of somatostatin 28 immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type. Brain Res 490: 1–13

    Article  CAS  PubMed  Google Scholar 

  107. Sun Q, Huguenard J, Prince D (2001) Neuropeptide Y receptors differentially modulate G-protein activated inwardly rectifying K+ channels and high voltage activated Ca2+ channels in rat thalamic neurons. J Physiol 531: 67–79

    CAS  PubMed  Google Scholar 

  108. Ellis Y, Davies J (2005) The effect of neuropeptides on the release of neurotransmitter amino acids from rat striatum. Neuropeptides 26: 65–69

    Google Scholar 

  109. McQuiston A, Petrozzino J, Connor J, Colmers W (1996) Neuropeptide Y1 receptors inhibit N-type calcium currents and reduce transient calcium increases in rat dentate granule cells. J Neurosci 16: 1422–1429

    CAS  PubMed  Google Scholar 

  110. Silva A, Carvalho A, Carvalho C, Malva J (2003) Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 44: 282–292

    Article  CAS  PubMed  Google Scholar 

  111. Silva A, Pinheiro P, Carvalho A, Carvalho C, Jakobsen B, Zimmer J, Malva J (2003) Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J 17: 1118–1121

    CAS  PubMed  Google Scholar 

  112. Silva A, Xapelli S, Pinheiro P, Ferreira R, Lourenco J, Ristovao A, Grouzmann E, Cavadas C, Oliveira C, Malva J (2005) Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats. J Neurochem 93: 163–170

    Article  CAS  PubMed  Google Scholar 

  113. Mody I, Pearce R (2004) Diversity of inhibitory neurotransmission through GABAA receptors Trends Neurosci 27: 569–575

    Article  CAS  PubMed  Google Scholar 

  114. Paulsen O, Moser E (1998) A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Trends Neurosci 21: 273–278

    Article  CAS  PubMed  Google Scholar 

  115. Kumar U, Asotra K, Patel A, Patel Y (1997) Expression of NMDA receptor-1 (NR1) and huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y and NADPH diaphorase: a double label histochemical and immunohistochemical study. Exp Neurol 145: 412–424

    Article  CAS  PubMed  Google Scholar 

  116. Zeron M, Hansson O, Chen N, Wellington C, Leavitt B, Brudin P, Hayden M, RAYMOND L (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 33: 849–860

    Article  CAS  PubMed  Google Scholar 

  117. Bryun R, Stoof J (1990) The quinolinic acid hypothesis in Huntington’s chorea. J Neurol Sci 95: 29–38

    Google Scholar 

  118. Colton C, Xu Q, Burke J, Bae S, Wakefield J, Nair A, Strittmatter W, Vitek M (2004) Disrupted spermine homeostasis: A novel mechanism in polyglutamine mediated aggregation and cell death. J Neurosci 24: 7118–7127

    Article  CAS  PubMed  Google Scholar 

  119. Deckel W, Gordinier A, Nuttal D, Tang D, Kuwada C, Frietas R, Gary K (2001) Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res 919: 70–81

    Article  CAS  PubMed  Google Scholar 

  120. Croisier E, Moran L, Dexter D, Pearce R, Graeber M (2005) Microglial inflammation in the parkinsonian substantia nigra: Relationship to alpha synculein deposition. J Neuroinflammation 2: 14–21

    Article  PubMed  Google Scholar 

  121. Eikelenboom P, Rosemuller JM, van Muiswinkel F (1998) Inflammation and Alzheimer’s disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 154: 89–98

    Article  CAS  PubMed  Google Scholar 

  122. Herrera A, Tomas-Camaradiel M, Venero J, Cano J, Machado A (2005) Inflammatory process as a determinant factor for the degeneration of substantia nigra dopamin ergic neurons. J Neural Transm 112: 111–119

    Article  CAS  PubMed  Google Scholar 

  123. Hirsch E, Hunot S, Hartmann A (2005) Neuroinflammatory processes in Parkinson’s disease. Parkinsonism Relat Disord 11: S9–S15

    Article  PubMed  Google Scholar 

  124. Kim Y, Kim S, Cho J, Choid D, Hwang O, Shin D, Chun H, Beal F, Joh T (2005) Matrix metalloproteinase-3: A novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 25: 3701–3711

    CAS  PubMed  Google Scholar 

  125. Topper R, Gehrmann J, Schwarz M, Block F, Noth J, Kreutzberg G (1993) Remote microglial activation in the quinolinic acid model of Huntington’s disease. Exp Neurol 123: 271–283

    CAS  PubMed  Google Scholar 

  126. Streit W, Colton CA (1995) The Brain’s immune system. Sci Amer 273: 38–44

    Google Scholar 

  127. Schwarz H, Villiger P, Kempis J, Lotz M (1994) Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 51: 53–61

    Article  CAS  PubMed  Google Scholar 

  128. Dureus P, Louis D, Grant A, Bilgfinger T, Stefano G (1993) Neuropeptide Y inhibits human and invertebrate immunocyte chemotaxis, chemokinesis, and spontaneous activation. Cell Mol Neurobiol 13: 541–546

    Article  CAS  PubMed  Google Scholar 

  129. Hosli E, Hosli L (1993) Autoradiographic localization of binding sites for neuropeptide Y and bradykinin on astrocytes. Neuroreport 4: 159–162

    CAS  PubMed  Google Scholar 

  130. Colton C, Gilbert D (1987) Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223: 284–288

    Article  CAS  PubMed  Google Scholar 

  131. Yao J, Gilbert D, Colton C (1990) Chemotaxis of cultured CNS microglia. J Neurosci Res 27: 36–42

    Article  CAS  PubMed  Google Scholar 

  132. Naveilhan P, Svensson L, Nystrom S, Ekstrant J, Ernfors P (2002) Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides 23: 1087–1091

    Article  CAS  PubMed  Google Scholar 

  133. Rohner-Jeanrenaud F (2000) Hormonal regulation of energy partitioning. Int H Obes Relat Metab Disord 24: S4–S7

    CAS  Google Scholar 

  134. Poehlman E, Dvorak R (2000) Energy expenditure. energy intake and weight loss in Alzheimer’s disease. Am J Clin Nutr 71: 650S–655S

    CAS  PubMed  Google Scholar 

  135. Walker F (2004) Targeting energy metabolism in Huntington’s disease. Lancet 364: 312–313

    Article  PubMed  Google Scholar 

  136. Nicholls D, Budd S (2000) Mitochondria and neuronal survival. Physiol Rev 80: 315–360

    CAS  PubMed  Google Scholar 

  137. Ojaimi J, Byrne E (2001) Mitochondrial function and Alzheimer’s disease. Biol Signals Recept 10: 254–262

    Article  CAS  PubMed  Google Scholar 

  138. Beal F, Howell N, Bodis-Wollner I (1997) Mitochondria and free radicals in neurodegenerative diseases. Wiley-Liss; New York

    Google Scholar 

  139. Orth M, Schapira A (2001) Mitochondria and degenerative disorders. Amer J Med Genet 106: 27–36

    Article  CAS  Google Scholar 

  140. Tabrizi S, Workman J, Hart P, Mangiarini L, Mahal A, Bates G, Cooper J, Schapira A (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47: 80–86

    Article  CAS  PubMed  Google Scholar 

  141. Silva A, Kaufmann J, Vivancos C, Faka S, Cavadas C, Shaw P, Brunner H, Vischer U, Grouzmann E (2005) Neuropeptide Y expression, localization and cellular transducing effects in HUVEC. Biol Cell 97: 457–467

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurology, Duke University Medical Center, Box 2900, Bryan Research Bldg, Durham, NC, 27710, USA

    Carol A. Colton & Michael P. Vitek

Authors
  1. Carol A. Colton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Vitek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Physiology and Biophysics, Georgetown University Medical Center, 3900 Reservoir Rd., NW, Washington, DC, 20057, USA

    Zofia Zukowska

  2. Wyeth Research, Building A3153, 500 Arcola Rd, Collegeville, PA, 19426, USA

    Giora Z. Feuerstein

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Colton, C.A., Vitek, M.P. (2006). NPY and chronic neurodegenerative disease. In: Zukowska, Z., Feuerstein, G.Z. (eds) NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders: from Genes to Therapeutics. Experientia Supplementum, vol 95. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7417-9_17

Download citation

Publish with us

Policies and ethics

Search

Navigation